[Edaily Reporter Kwon Oh Seok ] Amid a sharp drop of more than 5% in the U.S. Nasdaq index and a plunge of over 12% in the Philadelphia Semiconductor Index overnight, both SamsungElectronics(005930)and SK hynix(000660)are posting declines in the 10% range in premarket trading on the 6th. (Photo = Yonhap News) According to MP Doctor on the 6th, as of 8:20 a.m., SamsungElectronics(005930)is trading at 178,000 won, down 23,500 won (11.66%) from the previous trading day. At the same time, SK hynix(000660)is trading at 1,082,000 won, down 182,000 won (14.40%). Earlier, fears swept through the stock market that the policy climate in Washington would shift toward “stricter regulation of artificial intelligence (AI)” after the Democrats swept both the U.S. Senate and House of Representatives in the midterm elections. On the 5th (local time), the Dow Jones Industrial Average closed at 51,523.06 on the New York Stock Exchange (NYSE), down 3.44% from the previous trading day. The S&P 500 Index plummeted 4.36% to 7,353.73, while the tech-heavy Nasdaq Composite Index plunged 5.52% to 24,315.00. The market’s volatility index (VIX) surged 69% in a single day, clearly reflecting the panic sentiment across the market. The market decline was led by key stocks in the AI infrastructure value chain. Memory and semiconductor equipment stocks—SanDisk (-22.26%), Western Digital (-17.35%), and Micron (-17.46%)—all collapsed simultaneously. The Philadelphia Semiconductor Index plummeted by more than 12%. As a result, major domestic semiconductor stocks are also expected to be affected.
#Kbank’s new fixed-term deposit product, which allows customers to choose when they receive interest, has surpassed 1.1 trillion won in new deposits within just one month. With this product, customers…
Shinsegae Co.,Ltd has appointed Lee Seok-gu, the current CEO of Shinsegae DF, as the new head of its department store division. Through this appointment, the Shinsegae Department Store Division plans …
Aptabio Therapeutics Inc.(293780)has completed approximately 65% of patient enrollment for the domestic Phase 2b clinical trial of “Isuzinacxib” (APX-115), a treatment for diabetic nephropathy. As it …